BMO initiates Perspective Therapeutics stock at Outperform, $11 target

BMO Capital has taken a closer look at Perspective Therapeutics Inc (NYSE:CATX) and has deemed the company a strong buy, with an outperform rating and a target price of $11. This projection represents significant potential for the stock, which is currently trading at $3.21. Analysts have expressed a wide range of confidence, with price targets spanning from $5 to $18.

Perspective Therapeutics is pioneering precision radioligand therapies using its proprietary lead-212 platform and complementary imaging agents. The company's pipeline is spearheaded by bamzireotide navoxetan, which is already being evaluated for neuroendocrine tumors. Perspective Therapeutics is also exploring opportunities in melanoma and FAP-expressing solid tumors.

The firm sees substantial commercial potential in three key assets: VMT-α-NET, VMT01, and PSV359, driven by promising clinical, preclinical, and early human imaging data that have yet to be fully incorporated into market valuation. According to InvestingPro, five analysts have recently revised their earnings forecasts in an upward direction, bolstering the bullish outlook.

Additional insights for investors are available on the platform, including 10 ProTips and extensive financial data. Perspective Therapeutics has also recently been the subject of updates from other analysts. Piper Sandler lowered its price target to $14 from a previous $16, while retaining an overweight rating, following the company's Q2 2026 earnings report.

The report confirmed that the pivotal site activation for bamzireotide navoxetan is expected by the end of 2026. BTIG has also reiterated its Buy rating and maintained a $14 price target, highlighting the company's end-to-end Pb-212 manufacturing infrastructure as a significant competitive edge. The firm believes this infrastructure provides value beyond current market expectations.

These updates demonstrate the sustained interest and scrutiny from investment professionals regarding Perspective Therapeutics' growth prospects.